Advertisement

Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease

  • Jang-Wook Lee
  • Kwang-Hoon LeeEmail author
Nephrology - Original Paper
  • 80 Downloads

Abstract

Purpose

This study aimed to compare the renoprotective effect between febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease (CKD), about which limited data are available.

Methods

141 patients with stage 3 CKD and hyperuricemia were followed from June 2005 to April 2018. Thirty patients received febuxostat, 40 allopurinol and 71 conventional CKD management only (control group). We compared the mean serum uric acid levels, estimated glomerular filtration rate (eGFR) changes over time and renal survival time free from predefined renal disease progression among these 3 groups.

Results

Overall, mean age was 62.6 ± 13.3 years, baseline eGFR 42.1 ± 8.8 mL/min/1.73 m2, and serum uric acid 8.6 ± 1.5 mg/dL without intergroup difference. During the observation period (55.9 ± 31.8 months), febuxostat group, compared to both allopurinol and control group, had significantly lower mean serum uric acid levels (5.7 ± 1.0 vs. 7.1 ± 1.2 vs. 8.0 ± 0.8 mg/dL, p < 0.001) and maintained significantly higher mean eGFR values consistently for 4 years. Febuxostat group had significantly longer renal survival time free from renal disease progression than allopurinol and control group (87.7 (95% CI 71.2–104.2) vs. 77.6 (95% CI 60.2–94.9) vs. 48.7 (95% CI 39.3–58.1) months, respectively, p < 0.001). Cox proportional hazard model analysis adjusting for potent confounders revealed that febuxostat, with control group as reference, significantly reduced the risk of renal disease progression by 74.3% (hazard ratio 0.257 (95% CI 0.072–0.912), p = 0.036), while allopurinol showed insignificant result.

Conclusions

Febuxostat seems to reduce serum uric acid level and to retard renal disease progression more effectively than allopurinol in hyperuricemic patients with CKD.

Keywords

Febuxostat Allopurinol Hyperuricemia Renal insufficiency 

Notes

Funding

This study has not been financially supported by any specific fund.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

References

  1. 1.
    Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL et al (2001) Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38:1101–1106CrossRefGoogle Scholar
  2. 2.
    Nakagawa T, Mazzali M, Kang DH, Kanellis J, Watanabe S, Sanchez-Lozada LG et al (2001) Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 23:2–7CrossRefGoogle Scholar
  3. 3.
    Kuwabara M, Bjornstad P, Hisatome I, Niwa K, Roncal-Jimenez CA, Andres-Hernando A et al (2017) Elevated serum uric acid level predicts rapid decline in kidney function. Am J Nephrol 45:330–337CrossRefGoogle Scholar
  4. 4.
    Siu YP, Leung KT, Tong MK, Kwan TH (2006) Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47:51–59CrossRefGoogle Scholar
  5. 5.
    Kao MP, Ang DS, Gandy SJ, Nadir MA, Houston JG, Lang CC et al (2011) Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 22:1382–1389CrossRefGoogle Scholar
  6. 6.
    Shi Y, Chen W, Jalal D, Li Z, Chen W, Mao H et al (2012) Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial. Kidney Blood Press Res 35:153–160CrossRefGoogle Scholar
  7. 7.
    Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S et al (2015) Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, douoble-blind, randomized, placebo-controlled trial. Am J Kidney Dis 66:945–960CrossRefGoogle Scholar
  8. 8.
    Tanaka K, Nakayama M, Kanno M, Kimura H, Watanabe K, Tani Y et al (2015) Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial. Clin Exp Nephrol 19:1044–1053CrossRefGoogle Scholar
  9. 9.
    Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A et al (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Sic Nephrol 5:1388–1393CrossRefGoogle Scholar
  10. 10.
    Yood RA, Ottery FD, Irish W, Wolfson M (2014) Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials. BMC Res Notes 7:54.  https://doi.org/10.1186/1756-0500-7-54 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Halevy S, Ghislain PD, Mockenhaupt M et al (2008) Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 58:25–32CrossRefGoogle Scholar
  12. 12.
    Stamp LK, O’Donnell JL, Zhang M et al (2011) Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 63:412–421CrossRefGoogle Scholar
  13. 13.
    Edwards NL (2009) Febuxostat: a new treatment for hyperuricaemia in gout. Rheumatology 48(Suppl 2):ii15–ii19CrossRefGoogle Scholar
  14. 14.
    Hoshide S, Takahashi Y, Ishikawa T, Kubo J, Tsuchimoto M, Komoriya K, Ohno I, Hosoya T (2004) PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids 23:1117–1118CrossRefGoogle Scholar
  15. 15.
    Chohan S (2011) Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol 38:1957–1959CrossRefGoogle Scholar
  16. 16.
    Sezai A, Soma M, Nakata K, Hata M, Yoshitake I, Wakui S, Hata H, Shiono M (2013) Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU FLASH Trial). Circ J 77:2043–2049CrossRefGoogle Scholar
  17. 17.
    Tanaka K, Nakayama M, Kanno M, Kimura H, Watanabe K, Tani Y, Hayashi Y, Asahi K, Terawaki H, Watanabe T (2015) Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial. Clin Exp Nephrol 19:1044–1053CrossRefGoogle Scholar
  18. 18.
    Goldfarb DS, MacDonald PA, Gunawardhana L, Chefo S, McLean L (2013) Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones. Clin J Am Soc Nephrol 8:1960–1967CrossRefGoogle Scholar
  19. 19.
    Kim HA, Seo YI, Song YW (2014) Four-week effects of allopurinol and febuxostat treatments on blood pressure and serum creatinine level in gouty men. J Korean Med Sci 29:1077–1081CrossRefGoogle Scholar
  20. 20.
    No authors listed (2013) Chap. 1 Definition and classification of CKD. Kidney Int Suppl (2011) 3:19–62CrossRefGoogle Scholar
  21. 21.
    Glynn RJ, Campion EW, Silbert JE (1983) Trends in serum uric acid levels 1961–1980. Arthritis Rheum 26:87–93CrossRefGoogle Scholar
  22. 22.
    Levey AS, Stevens LA (2010) Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis 55:622–627CrossRefGoogle Scholar
  23. 23.
    Altan A, Shiozawa A, Bancroft T, Singh JA (2015) A real-world study of switching from allopurinol to Febxostat in a health plan database. J Clin Rheumatol 21:411–418CrossRefGoogle Scholar
  24. 24.
    Abeles AM (2012) Febuxostat hypersensitivity. J Rheumatol 39:659CrossRefGoogle Scholar
  25. 25.
    Bardin T, Chales G, Pascart T, Flipo RM, Korng Ea H, Roujeau JC, Delayen A, Clerson P (2016) Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. Joint Bone Spine 83:314–317CrossRefGoogle Scholar
  26. 26.
    Tsuruta Y, Mochizuki T, Moriyama T, Itabashi M, Takei T, Tsuchiya K et al (2014) Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease. Clin Rheumatol 33:1643–1648CrossRefGoogle Scholar
  27. 27.
    Sakai Y, Otsuka T, Ohno D, Murasawa T, Sato N, Tsuruoka S (2014) Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease. Ren Fail 36:225–231CrossRefGoogle Scholar
  28. 28.
    Chou HW, Chiu HT, Tsai CW, Ting IW, Yeh HC, Huang HC et al (2017) Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study. Nephrol Dial Transplant.  https://doi.org/10.1093/ndt/gfx313 CrossRefPubMedGoogle Scholar
  29. 29.
    Goicoechea M, Garcia de Vinuesa S, Verdalles U, Verde E, Macias N, Santos A et al (2015) Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. Am J Kidney Dis 65:543–549CrossRefGoogle Scholar
  30. 30.
    Gondouin B, Jourde-Chiche N, Sallee M, Dou L, Cerini C, Loundou A et al (2015) Plasma xanthin oxidase activity is predictive of cardiovascular disease in patients with chronic kidney disease, independently of uric acid levels. Nephron 131:167–174CrossRefGoogle Scholar
  31. 31.
    Miao H, Tomlinson B (2008) Febuxostat in the management of hyperuricemia and chronic gout: a review. Ther Clin Risk Manag 4:1209–1220CrossRefGoogle Scholar
  32. 32.
    White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A et al (2018) Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 378:1200–1210CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Department of Internal MedicineDongguk University Ilsan HospitalGoyangSouth Korea

Personalised recommendations